SML0816
普拉西坦
≥98% (HPLC)
别名:
Amacetam, N-[2-(Diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide, N-[2-[Bis(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide, Vinpotropil
SMILES string
[S](=O)(=O)([O-])O.[N+H](C(C)C)(C(C)C)CCNC(=O)CN1CCCC1=O
InChI
1S/C14H27N3O2.H2O4S/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19;1-5(2,3)4/h11-12H,5-10H2,1-4H3,(H,15,18);(H2,1,2,3,4)
InChI key
ACSROKXFXFNERX-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: 10 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Pramiracetam is a potent nootropic agent that is a member of the racetam drug family. Pramiracetam improves cognitive deficits associated with traumatic brain injuries. Also, pramiracetam is a specific inhibitor of prolyl endopeptidase.
Pramiracetam is a potent nootropic agent.
Pramiracetam plays an important role in spatial learning and memory in rats. It is considered as a memory enhancing agent and is stronger than piracetam.
Features and Benefits
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
A J Gower et al.
Neuropharmacology, 25(10), 1161-1166 (1986-10-01)
Rats were tested for tail-flick responses and then immediately subjected to footshock for 30 sec. This procedure induced analgesia, i.e. prolonged the latency of the tail-flick response, which was maximal immediately after the shock and decayed to normal levels within
T Chang et al.
Journal of clinical pharmacology, 25(4), 291-295 (1985-05-01)
The pharmacokinetics of pramiracetam, a new, investigational, cognition activator, were assessed in normal male volunteers as part of a clinical tolerance study. In a double-blind, randomized design, two groups of six subjects each received alternating placebo and single 400, 800
L A Dziak et al.
Likars'ka sprava, (8)(8), 67-72 (2004-02-18)
Morbidity rise of cerebrovascular pathology is followed by remarkable cognitive decline. Chronic cerebral blood insufficiency and stroke consequences compose a group of the diseases which lead to different types of memory deterioration, consecutive memory decline and as a result to
C Mondadori et al.
Behavioural brain research, 33(1), 79-82 (1989-05-01)
The effects of the nootropic agent piracetam and its congeners oxiracetam, pramiracetam and aniracetam on the retention performance of mice in a passive-avoidance situation are dependent on the intensity of the foot-shock applied. This phenomenon is observed upon both pre-trial
J J Claus et al.
Neurology, 41(4), 570-574 (1991-04-01)
The cognitive-enhancing effects of pramiracetam in animal models of learning and memory are characterized by an inverted U-shaped dose-response curve. We evaluated antidementia efficacy of this drug in 10 patients with probable Alzheimer's disease employing a 2-phase, placebo-controlled, enrichment-type trial
商品
DISCOVER Bioactive Small Molecules for Neuroscience
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持